Cancer in bone and bone metastasis significantly contributes to cancer mortality worldwide by causing more than 1 million deaths annually. There are to date, essentially no curative therapeutic options for patients suffering from advanced bone cancer and bone metastasis. Pioneer transcription factor complexes, which are proteins that have the ability to initiate new gene expression programs, are dysregulated in cancer and often linked to cancer aggressiveness, metastasis, and treatment resistance. Developing effective, curative treatment strategies for bone metastasis is required to decrease worldwide cancer mortality.
Our lead product, PR-2304, is targeting a key transcription factor complex driving bone metastasis development. The inhibitor kills cancer cells through multifactorial mechanisms and shows great therapeutic potential. PR-2304 is currently in the pre-clinical stage of development.